Patents Assigned to Wake Forest University
  • Patent number: 11013825
    Abstract: A method of making an organ or tissue comprises: (a) providing a first dispenser containing a structural support polymer and a second dispenser containing a live cell-containing composition; (b) depositing a layer on said support from said first and second dispenser, said layer comprising a structural support polymer and said cell-containing composition; and then (c) iteratively repeating said depositing step a plurality of times to form a plurality of layers one on another, with separate and discrete regions in each of said layers comprising one or the other of said support polymer or said cell-containing composition, to thereby produce provide a composite three dimensional structure containing both structural support regions and cell-containing regions. Apparatus for carrying out the method and composite products produced by the method are also described.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: May 25, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Hyun-Wook Kang, Sang Jin Lee, Anthony Atala, James J. Yoo
  • Patent number: 11013828
    Abstract: The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: May 25, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Anthony Atala, James Yoo, In Kap Ko
  • Patent number: 11001811
    Abstract: Provided herein are artificial lung organoids. The artificial lung organoids may include an epithelial cell layer comprising mammalian lung epithelial cells, a stromal cell layer comprising mammalian lung fibroblast cells and an endothelial cell layer comprising mammalian endothelial cells. The artificial lung organoids may optionally include a porous membrane between said epithelial cell layer and said stromal cell layer and/or between said stromal cell layer and said endothelial lung cell layer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 11, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Sean V. Murphy, Anthony Atala
  • Patent number: 10993433
    Abstract: A cell composition composed of spermatogonial stem cells, Sertoli cells, Leydig cells and optionally peritubular cells, is provided, as is a culture composition, artificial testicular construct, hydrogel composition, and device containing the same. A method for using the device as a physiologically relevant in vitro model of human testicular function to screen compounds for pharmacological or toxicological activity is also provided.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 4, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Samuel Pendergraft, Hooman Sadri-Ardekani, Anthony Atala, Colin Bishop
  • Patent number: 10967009
    Abstract: The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: April 6, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Sean V. Murphy, Aleksander Skardal, Anthony Atala
  • Patent number: 10959835
    Abstract: Medical kits and methods for performing small incision DLEK include a corneal transplantation donor tissue graft formed into an implantable and compact rolled configuration using the flexible substrate.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: March 30, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Keith Andrew Walter, Kurt Weber
  • Patent number: 10949973
    Abstract: Post-image acquisition methods, circuits and systems for evaluating medical images of a subject register a region of interest in a first medical image taken at a first point in time to the region of interest in a second image taken before or after the first medical image with voxels from the first and second medical images having a voxel-wise correspondence. The methods, circuits and systems can use line and/or shape changes of defined 3-D finite elements to electronically determine directional, shear and volumetric changes of the voxels in the region of interest between the first and second medical images.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 16, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Jeongchul Kim, Youngkyoo Jung, Christopher T. Whitlow
  • Patent number: 10941385
    Abstract: The present invention relates to recombinant vectors, modified microorganisms, and methods for omega-3 polyunsaturated fatty acid production.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 9, 2021
    Assignee: Wake Forest University
    Inventors: Leslie B. Poole, Floyd H. Chilton, Derek Parsonage, Susan Sergeant
  • Patent number: 10925831
    Abstract: This invention relates to use of a platinum-acridine liposomal formulation and uses thereof in treating cancer in a subject.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: February 23, 2021
    Assignee: Wake Forest University
    Inventors: Ulrich Bierbach, Song Ding, Christopher L. Hackett
  • Publication number: 20210046197
    Abstract: The present invention is directed to radiopharmaceuticals with improved stability, a kit, and a method of production thereof.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 18, 2021
    Applicant: Wake Forest University
    Inventors: Thaddeus J. Wadas, Nikunj B. Bhatt, Darpan N. Pandya
  • Patent number: 10870526
    Abstract: Solid particulate measuring devices, systems, and methods for using the devices and systems are provided for easier and more accurate measurement of specific volumes. For example, a specific dose of a pharmaceutical multiparticulate composition can be measured out accurately and easily in a variety of settings using the devices and systems described herein.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: December 22, 2020
    Assignee: Wake Forest University Health Sciences
    Inventor: Arjun Patel
  • Patent number: 10868077
    Abstract: In some embodiments, thermoelectric apparatus and various applications of thermoelectric apparatus are described herein. In some embodiments, a thermoelectric apparatus described herein comprises at least one p-type layer coupled to at least one n-type layer to provide a pn junction, and an insulating layer at least partially disposed between the p-type layer and the n-type layer, the p-type layer comprising a plurality of carbon nanoparticles and the n-type layer comprising a plurality of n-doped carbon nanoparticles.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: December 15, 2020
    Assignee: Wake Forest University
    Inventor: David L Carroll
  • Publication number: 20200377551
    Abstract: Peptide constructs comprising a mitochondrial antiviral-signaling protein (MAVS) peptide and a cell penetration peptide are disclosed, which are useful for stimulating interferon production in vitro and in vivo. Lactate has been discovered to inhibit glycolysis-mediated retinoic acid-inducible gene I (RIG-I) like receptor signaling by directly binding to the MAVS transmembrane (TM) domain and preventing MAVS aggregation; peptide constructs according to the disclosure can prevent or reverse this inhibition to stimulate interferon production. Methods for stimulating interferon production in a cell are also described, as well as methods for the treatment of viral infections and cancer.
    Type: Application
    Filed: May 22, 2020
    Publication date: December 3, 2020
    Applicant: Wake Forest University Health Sciences
    Inventors: Hui-Kuan Lin, Weina Zhang, Guihua Wang
  • Patent number: 10828143
    Abstract: Methods are disclosed for forming tissue engineered, tubular bowel constructs from intestinal circular smooth muscle cells and enteric neural progenitor cells. The intestinal smooth muscle cells and neural progenitor cells can be seeded on a mold with a surface texture that induces longitudinal alignment of the intestinal smooth muscle cells and co-cultured until an innervated aligned smooth muscle sheet is obtained. The innervated smooth muscle sheet can then be wrapped around a tubular scaffold to form an intestinal tissue construct.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: November 10, 2020
    Assignee: Wake Forest University Health Sciences
    Inventor: Khalil Bitar
  • Patent number: 10821211
    Abstract: Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 3, 2020
    Assignee: Wake Forest University Health Sciences
    Inventor: Mark E. Van Dyke
  • Patent number: 10766970
    Abstract: Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: September 8, 2020
    Assignees: Wake Forest University Health Sciences, Wake Forest University
    Inventors: Mark E. Welker, Emmanuel C. Opara, Surya R. Banks, Amber N. Weissenfluh
  • Patent number: 10758634
    Abstract: Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeutic oncology treatments relative to the presently available chelator compositions due to a variety of superior properties of the disclosed compositions. The present invention also relates to a superior method of making these compounds, complexes, compositions that allows one to make compounds/complexes (and thus, compositions) that were previously unattainable.
    Type: Grant
    Filed: March 18, 2017
    Date of Patent: September 1, 2020
    Assignee: Wake Forest University
    Inventors: Thaddeus J. Wadas, Darpan N. Pandya, Nikunj B. Bhatt
  • Patent number: 10752667
    Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R?2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: August 25, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Carla Lema Tome, Sara Ferluga, Poonam S. Sonawane
  • Publication number: 20200261419
    Abstract: Provided herein are methods of treatment for kidney stones, e.g., for controlling or inhibiting the formation of calcium oxalate kidney stones by inhibiting the production of glyoxylate and/or oxalate, treatment of primary hyperoxaluria, etc. In some embodiments, methods comprise administering to a subject in need thereof, in combination, an inhibitor of hydroxyproline dehydrogenase (HYPDH), an inhibitor of glycolate oxidase (GO), and/or another agent for the treatment of kidney stones. Compositions for such use or the use of active agents in the manufacture of a medicament for the treatment of kidney stones are also provided.
    Type: Application
    Filed: December 7, 2016
    Publication date: August 20, 2020
    Applicant: Wake Forest University Health Sciences
    Inventors: W. Todd Lowther, Ross P. Holmes, Daniel Yohannes
  • Patent number: 10736945
    Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: August 11, 2020
    Assignees: Wake Forest University Health Sciences, Genethon, Children's Medical Center Corporation
    Inventors: Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello